QQ客服 官方微博 反馈留言

	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
	Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin
刊名	LANCET ONCOLOGY
	2018
卷号	19期号:1
ISSN号	1470-2045
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3609740
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhong, Wen-Zhao,Wang, Qun,Mao, Wei-Min,et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. LANCET ONCOLOGY,2018,19(1).
APA	Zhong, Wen-Zhao.,Wang, Qun.,Mao, Wei-Min.,Xu, Song-Tao.,Wu, Lin.,...&Wu, Yi-Long.(2018).Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.LANCET ONCOLOGY,19(1).
MLA	Zhong, Wen-Zhao,et al."Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study".LANCET ONCOLOGY 19.1(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。